<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3106">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315480</url>
  </required_header>
  <id_info>
    <org_study_id>TOCICOV-1</org_study_id>
    <nct_id>NCT04315480</nct_id>
  </id_info>
  <brief_title>Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis</brief_title>
  <official_title>Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Ospedali Riuniti Marche Nord</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered
      as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia
      correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an
      anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking
      deterioration of lung function or even promoting a rapid improvement of clinical conditions,
      preventing naso-tracheal intubation and/or death.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Simon's Two-stages Optimal Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Radiologist will be blinded for sequence</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>arrest in deterioration of pulmonary function</measure>
    <time_frame>7days</time_frame>
    <description>rate of patients with no need in increase of FiO2 to maintain stable SO2 and no need of intubation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improving in pulmonary function</measure>
    <time_frame>7 days</time_frame>
    <description>rate of patients with change of oxygen saturation &gt;3 percentage points or &gt;10% or decrease in FiO2 need or reduction in pulmonary consolidations &gt;30% at HR CT-scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>need of oro-tracheal intubation</measure>
    <time_frame>+7 days</time_frame>
    <description>rate of patients needed of intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>14days</time_frame>
    <description>rate of patients dead</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>SARS Pneumonia</condition>
  <arm_group>
    <arm_group_label>tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>single intravenous administration 8mg/Kg</description>
    <arm_group_label>tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-CoV2 Infection diagnosed by rt-PCR

          -  CT-scan confirmed multifocal interstitial pneumonia

          -  Need of oxygen therapy to maintain SO2&gt;93%

          -  Worsening of lung involvement, defined as (one of the following criteria):

               -  Worsening of oxygen saturation &gt;3 percentage points or decrease in PaO2 &gt;10%,
                  with stable FiO2 in the last 24h

               -  Need of increase FiO2 in order to maintain a stable SO2 or new onset need of
                  mechanical ventilation in the last 24h

               -  Increase in number and/or extension of pulmonary areas of consolidation

        Exclusion Criteria:

          -  Age &lt;18 ys and &gt;90 ys

          -  Severe heart failure

          -  Bacterial Infection

          -  Haematological neoplasm

          -  Neutrophil count below 1000/mcl

          -  Platelet count below 50000/mcl

          -  ALT&gt; x5UNL

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Università Politecnica delle Marche</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.</citation>
    <PMID>32114094</PMID>
  </reference>
  <reference>
    <citation>Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020 Mar 4;9(3). pii: E186. doi: 10.3390/pathogens9030186. Review.</citation>
    <PMID>32143502</PMID>
  </reference>
  <reference>
    <citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2. Review.</citation>
    <PMID>28466096</PMID>
  </reference>
  <reference>
    <citation>Zumla A, Ippolito G, Ntoumi F, Seyfert-Margolies V, Nagu TJ, Cirillo D, Chakaya JM, Marais B, Maeurer M. Host-directed therapies and holistic care for tuberculosis. Lancet Respir Med. 2020 Apr;8(4):337-340. doi: 10.1016/S2213-2600(20)30078-3. Epub 2020 Feb 27.</citation>
    <PMID>32113574</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Politecnica delle Marche</investigator_affiliation>
    <investigator_full_name>Armando Gabrielli</investigator_full_name>
    <investigator_title>Full Professor Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

